Krystal Biotech (KRYS) Stock Forecast & Price Target

Compare

532 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KRYS Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Krystal

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KRYS Stock 12 Month Forecast

Average Price Target

$198.00

▲(31.87%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $198.00 with a high forecast of $240.00 and a low forecast of $176.00. The average price target represents a 31.87% change from the last price of $150.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","241":"$241","153.25":"$153.3","182.5":"$182.5","211.75":"$211.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$198.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$176.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,153.25,182.5,211.75,241],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.01,146.77846153846153,154.54692307692306,162.3153846153846,170.08384615384614,177.85230769230768,185.6207692307692,193.38923076923078,201.1576923076923,208.92615384615385,216.69461538461536,224.46307692307693,232.23153846153846,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.01,143.5476923076923,148.0853846153846,152.62307692307692,157.16076923076923,161.69846153846154,166.23615384615385,170.77384615384614,175.31153846153848,179.84923076923076,184.3869230769231,188.92461538461538,193.4623076923077,{"y":198,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.01,141.8553846153846,144.70076923076923,147.54615384615383,150.39153846153846,153.23692307692306,156.0823076923077,158.9276923076923,161.77307692307693,164.61846153846153,167.46384615384616,170.30923076923077,173.1546153846154,{"y":176,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":182.27,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.78,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.91,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$240.00

Average Price Target$198.00

Lowest Price Target$176.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$171

Buy

13.89%

Upside

Reiterated

07/10/25

Krystal Biotech's overall stock score is driven by strong financial performance and positive earnings call insights, highlighting significant revenue growth and strategic market expansions. Technical indicators and valuation reflect cautious optimism, while recent corporate events signal promising future developments.

Ritu BaralTD Cowen

TD Cowen

$202

Buy

34.53%

Upside

Reiterated

07/10/25

TD Cowen Sticks to Their Buy Rating for Krystal Biotech (KRYS)

Yigal NochomovitzCiti

Citi

$155→$176

Hold

17.22%

Upside

Reiterated

07/09/25

Cautious Optimism for Krystal Biotech's KB801 Amidst Uncertain Efficacy Data

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

07/09/25

Optimistic Buy Rating for Krystal Biotech Driven by Innovative Gene Therapy KB801 for Neurotrophic Keratitis

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$240

Buy

59.84%

Upside

Reiterated

07/09/25

Promising Market Potential and Innovative Approach Drive Buy Rating for Krystal Biotech's Gene Therapy KB801

William MaughanClear Street

Clear Street

$190

Buy

26.54%

Upside

Initiated

06/30/25

Krystal Biotech initiated with a Buy at Clear StreetKrystal Biotech initiated with a Buy at Clear Street

Andrea NewkirkGoldman Sachs

Goldman Sachs

$194

Buy

29.20%

Upside

Reiterated

06/11/25

Krystal Biotech's Promising Growth and Strategic Initiatives Support Buy Rating

Alec StranahanBank of America Securities

Bank of America Securities

$193

Buy

28.54%

Upside

Reiterated

05/16/25

Bank of America Securities Sticks to Its Buy Rating for Krystal Biotech (KRYS)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$200

Buy

33.20%

Upside

Reiterated

05/12/25

Krystal Biotech (KRYS) Receives a Buy from Evercore ISI

Debjit ChattopadhyayGuggenheim

Guggenheim

$195→$189

Buy

25.87%

Upside

Reiterated

05/07/25

Krystal Biotech price target lowered to $189 from $195 at GuggenheimKrystal Biotech price target lowered to $189 from $195 at Guggenheim

Roger SongJefferies

Jefferies

$245

Buy

63.17%

Upside

Initiated

03/05/25

Krystal Biotech's Growth Potential: Strong Vyjuvek Launch and Promising PipelineWe see steady growth to achieve blockbuster status in few years, deepening penetration by accessing global and ocular market. Co has many dev program in CF/ AATD/ oncology/ dermatology based on proprietary, in house gene delivery technology to drive add'l upside. We initiate at Buy with PT of $245.

Geulah LivshitsChardan Capital

Chardan Capital

$212→$218

Buy

45.19%

Upside

Reiterated

02/19/25

Krystal Biotech price target raised to $218 from $212 at ChardanKrystal Biotech price target raised to $218 from $212 at Chardan

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$220

Buy

46.52%

Upside

Reiterated

11/05/24

Stifel Nicolaus Sticks to Their Buy Rating for Krystal Biotech (KRYS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$171

Buy

13.89%

Upside

Reiterated

07/10/25

Ritu BaralTD Cowen

TD Cowen

$202

Buy

34.53%

Upside

Reiterated

07/10/25

TD Cowen Sticks to Their Buy Rating for Krystal Biotech (KRYS)

Yigal NochomovitzCiti

Citi

$155→$176

Hold

17.22%

Upside

Reiterated

07/09/25

Cautious Optimism for Krystal Biotech's KB801 Amidst Uncertain Efficacy Data

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

07/09/25

Optimistic Buy Rating for Krystal Biotech Driven by Innovative Gene Therapy KB801 for Neurotrophic Keratitis

Joseph PantginisH.C. Wainwright

H.C. Wainwright

$240

Buy

59.84%

Upside

Reiterated

07/09/25

Promising Market Potential and Innovative Approach Drive Buy Rating for Krystal Biotech's Gene Therapy KB801

William MaughanClear Street

Clear Street

$190

Buy

26.54%

Upside

Initiated

06/30/25

Krystal Biotech initiated with a Buy at Clear StreetKrystal Biotech initiated with a Buy at Clear Street

Andrea NewkirkGoldman Sachs

Goldman Sachs

$194

Buy

29.20%

Upside

Reiterated

06/11/25

Krystal Biotech's Promising Growth and Strategic Initiatives Support Buy Rating

Alec StranahanBank of America Securities

Bank of America Securities

$193

Buy

28.54%

Upside

Reiterated

05/16/25

Bank of America Securities Sticks to Its Buy Rating for Krystal Biotech (KRYS)

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$200

Buy

33.20%

Upside

Reiterated

05/12/25

Krystal Biotech (KRYS) Receives a Buy from Evercore ISI

Debjit ChattopadhyayGuggenheim

Guggenheim

$195→$189

Buy

25.87%

Upside

Reiterated

05/07/25

Krystal Biotech price target lowered to $189 from $195 at GuggenheimKrystal Biotech price target lowered to $189 from $195 at Guggenheim

Roger SongJefferies

Jefferies

$245

Buy

63.17%

Upside

Initiated

03/05/25

Geulah LivshitsChardan Capital

Chardan Capital

$212→$218

Buy

45.19%

Upside

Reiterated

02/19/25

Krystal Biotech price target raised to $218 from $212 at ChardanKrystal Biotech price target raised to $218 from $212 at Chardan

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$220

Buy

46.52%

Upside

Reiterated

11/05/24

Stifel Nicolaus Sticks to Their Buy Rating for Krystal Biotech (KRYS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Krystal Biotech

1 Month

xxx

Success Rate

8/11 ratings generated profit

Average Return

+1.85%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +1.85% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+2.33%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +2.33% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

13/16 ratings generated profit

Average Return

+41.68%

reiterated a buy rating 5 months ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +41.68% per trade.

2 Years

xxx

Success Rate

13/16 ratings generated profit

Average Return

+85.53%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +85.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRYS Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KRYS has received 19 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. KRYS average Analyst price target in the past 3 months is 198.00.

Each month's total comprises the sum of three months' worth of ratings.

KRYS Financial Forecast

KRYS Earnings Forecast

Next quarter’s earnings estimate for KRYS is $1.21 with a range of $0.95 to $1.63. The previous quarter’s EPS was $1.20. KRYS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year KRYS has Outperformed its overall industry.

KRYS Sales Forecast

Next quarter’s sales forecast for KRYS is $92.01M with a range of $89.96M to $95.00M. The previous quarter’s sales results were $88.18M. KRYS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year KRYS has Outperformed its overall industry.

KRYS Stock Forecast FAQ

What is KRYS’s average 12-month price target, according to analysts?

Based on analyst ratings, Krystal Biotech’s 12-month average price target is 198.00.

What is KRYS’s upside potential, based on the analysts’ average price target?

Krystal Biotech has 31.87% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KRYS a Buy, Sell or Hold?

Krystal Biotech has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Krystal Biotech’s price target?

The average price target for Krystal Biotech is 198.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $240.00 ,the lowest forecast is $176.00. The average price target represents 31.87% Increase from the current price of $150.15.

What do analysts say about Krystal Biotech?

Krystal Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of KRYS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Krystal Biotech (KRYS) Stock Forecast & Price Target

KRYS Analyst Ratings

KRYS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Krystal Biotech

KRYS Analyst Recommendation Trends

KRYS Financial Forecast

KRYS Earnings Forecast

KRYS Sales Forecast

KRYS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts